Analysts Set GH Research PLC (NASDAQ:GHRS) Target Price at $40.13

GH Research PLC (NASDAQ:GHRS) has been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $40.1250.

A number of brokerages have issued reports on GHRS. Wolfe Research set a $39.00 price target on GH Research in a research note on Tuesday, January 6th. Royal Bank Of Canada lifted their target price on GH Research from $33.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research report on Thursday, January 22nd. Guggenheim set a $34.00 target price on shares of GH Research and gave the stock a “buy” rating in a report on Tuesday, March 10th. Finally, Canaccord Genuity Group increased their target price on shares of GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th.

GH Research Stock Down 1.4%

GHRS stock opened at $14.81 on Tuesday. The company has a 50-day simple moving average of $15.66 and a 200 day simple moving average of $14.37. The company has a market capitalization of $918.66 million, a P/E ratio of -18.51 and a beta of 1.00. GH Research has a fifty-two week low of $7.98 and a fifty-two week high of $19.51.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.06. Equities analysts anticipate that GH Research will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

A number of institutional investors and hedge funds have recently modified their holdings of GHRS. Barclays PLC boosted its position in shares of GH Research by 63.4% in the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock valued at $27,000 after purchasing an additional 822 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in GH Research during the 4th quarter worth about $38,000. Osaic Holdings Inc. lifted its stake in GH Research by 63.6% during the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock valued at $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in GH Research during the second quarter valued at about $79,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of GH Research in the second quarter worth about $89,000. 56.90% of the stock is owned by institutional investors and hedge funds.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.